Neuroendocrine Carcinoma/Small Cell Carcinoma clinical trials at UCSD

• Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

  open to eligible people ages 18 years and up

  This research study is studying a combination of drugs as a possible treatment for rare genitourinary malignancies. -The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab

  La Jolla, California and other locations

Last updated: April 6, 2020